FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1433900029> ?p ?o ?g. }

• W1433900029 endingPage "1863" @default.
• W1433900029 startingPage "1863" @default.
• W1433900029 abstract "Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis Eline L Huisman,1 Sarah M Cockle,2 Afisi S Ismaila,3,4 Andreas Karabis,1 Yogesh Suresh Punekar2 1Mapi Group, Real World Strategy and Analytics and Strategic Market Access, Houten, the Netherlands; 2Value Evidence and Outcomes, GlaxoSmithKline, Uxbridge, UK; 3Value Evidence and Outcomes, GlaxoSmithKline R&D, Research Triangle Park, NC, USA; 4Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada Background: Several new fixed-dose combination bronchodilators have been recently launched, and assessing their efficacy relative to each other, and with open dual combinations is desirable. This network meta-analysis (NMA) assessed the efficacy of umeclidinium and vilanterol (UMEC/VI) with that of available dual bronchodilators in single/separate inhalers. Methods: A systematic literature review identified randomized controlled trials of ≥10 weeks among chronic obstructive pulmonary disease patients (≥40 years), assessing the efficacy of combination bronchodilators in single or separate inhalers. Comparative assessment was conducted on change from baseline in trough forced expiratory volume in 1 second (FEV1), St George’s Respiratory Questionnaire (SGRQ) total scores, transitional dyspnea index (TDI) focal scores, and rescue medication use at 12 weeks and 24 weeks using an NMA within a Bayesian framework. Results: A systematic literature review identified 77 articles of 26 trials comparing UMEC/VI, indacaterol/glycopyrronium (QVA149), formoterol plus tiotropium (TIO) 18 µg, salmeterol plus TIO, or indacaterol plus TIO, with TIO and placebo as common comparators at 12 weeks and approximately 24 weeks. The NMA showed that at 24 weeks, efficacy of UMEC/VI was not significantly different compared with QVA149 on trough FEV1 (14.1 mL [95% credible interval: -14.2, 42.3]), SGRQ total score (0.18 [-1.28, 1.63]), TDI focal score (-0.30 [-0.73, 0.13]), and rescue medication use (0.02 [-0.27, 0.32]); compared with salmeterol plus TIO on trough FEV1 (67.4 mL [-25.3, 159.4]), SGRQ total score (-0.11 [-1.84, 1.61]), and TDI focal score (0.58 [-0.33, 1.50]); and compared with formoterol plus TIO 18 µg on SGRQ total score (-0.68 [-1.77, 0.39]). Results at week 12 were consistent with week 24 outcomes. Due to lack of availability of evidence, no comparison was made with formoterol plus TIO on FEV1 or TDI at 24 weeks. Conclusion: UMEC/VI has comparable efficacy to other dual-bronchodilator combinations on available efficacy endpoints. Keywords: LABA/LAMA, UMEC/VI, QVA149, fomoterol, tiotropium, glycopyrronium, indacaterol, umeclidinium" @default.
• W1433900029 created "2016-06-24" @default.
• W1433900029 creator A5001789783 @default.
• W1433900029 creator A5030471784 @default.
• W1433900029 creator A5067179752 @default.
• W1433900029 creator A5067651492 @default.
• W1433900029 creator A5083332623 @default.
• W1433900029 date "2015-09-01" @default.
• W1433900029 modified "2023-09-25" @default.
• W1433900029 title "Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis" @default.
• W1433900029 cites W1704063072 @default.
• W1433900029 cites W1719195715 @default.
• W1433900029 cites W1954671479 @default.
• W1433900029 cites W1963720710 @default.
• W1433900029 cites W1966561347 @default.
• W1433900029 cites W1971649226 @default.
• W1433900029 cites W1980789906 @default.
• W1433900029 cites W1980922801 @default.
• W1433900029 cites W1981197711 @default.
• W1433900029 cites W1990795619 @default.
• W1433900029 cites W2004474087 @default.
• W1433900029 cites W2005640821 @default.
• W1433900029 cites W2006528231 @default.
• W1433900029 cites W2014443443 @default.
• W1433900029 cites W2025133561 @default.
• W1433900029 cites W2026585673 @default.
• W1433900029 cites W2029276834 @default.
• W1433900029 cites W2037965009 @default.
• W1433900029 cites W2039237831 @default.
• W1433900029 cites W2051449385 @default.
• W1433900029 cites W2070935883 @default.
• W1433900029 cites W2104636056 @default.
• W1433900029 cites W2105234929 @default.
• W1433900029 cites W2113026917 @default.
• W1433900029 cites W2116505643 @default.
• W1433900029 cites W2120356269 @default.
• W1433900029 cites W2122286642 @default.
• W1433900029 cites W2123850585 @default.
• W1433900029 cites W2125779455 @default.
• W1433900029 cites W2127789103 @default.
• W1433900029 cites W2133080325 @default.
• W1433900029 cites W2141034778 @default.
• W1433900029 cites W2142430815 @default.
• W1433900029 cites W2142449488 @default.
• W1433900029 cites W2142633372 @default.
• W1433900029 cites W2149199480 @default.
• W1433900029 cites W2150529573 @default.
• W1433900029 cites W2158795682 @default.
• W1433900029 cites W2163053179 @default.
• W1433900029 cites W2165446260 @default.
• W1433900029 cites W2165909321 @default.
• W1433900029 cites W2171280425 @default.
• W1433900029 cites W2171974515 @default.
• W1433900029 cites W4239080780 @default.
• W1433900029 doi "https://doi.org/10.2147/copd.s87082" @default.
• W1433900029 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4573199" @default.
• W1433900029 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26392761" @default.
• W1433900029 hasPublicationYear "2015" @default.
• W1433900029 type Work @default.
• W1433900029 sameAs 1433900029 @default.
• W1433900029 citedByCount "9" @default.
• W1433900029 countsByYear W14339000292016 @default.
• W1433900029 countsByYear W14339000292017 @default.
• W1433900029 countsByYear W14339000292018 @default.
• W1433900029 countsByYear W14339000292019 @default.
• W1433900029 crossrefType "journal-article" @default.
• W1433900029 hasAuthorship W1433900029A5001789783 @default.
• W1433900029 hasAuthorship W1433900029A5030471784 @default.
• W1433900029 hasAuthorship W1433900029A5067179752 @default.
• W1433900029 hasAuthorship W1433900029A5067651492 @default.
• W1433900029 hasAuthorship W1433900029A5083332623 @default.
• W1433900029 hasBestOaLocation W14339000291 @default.
• W1433900029 hasConcept C126322002 @default.
• W1433900029 hasConcept C142724271 @default.
• W1433900029 hasConcept C168563851 @default.
• W1433900029 hasConcept C1862650 @default.
• W1433900029 hasConcept C204787440 @default.
• W1433900029 hasConcept C27081682 @default.
• W1433900029 hasConcept C2776042228 @default.
• W1433900029 hasConcept C2776719499 @default.
• W1433900029 hasConcept C2776780178 @default.
• W1433900029 hasConcept C2778884479 @default.
• W1433900029 hasConcept C2779028295 @default.
• W1433900029 hasConcept C2780911369 @default.
• W1433900029 hasConcept C2781018748 @default.
• W1433900029 hasConcept C71924100 @default.
• W1433900029 hasConceptScore W1433900029C126322002 @default.
• W1433900029 hasConceptScore W1433900029C142724271 @default.
• W1433900029 hasConceptScore W1433900029C168563851 @default.
• W1433900029 hasConceptScore W1433900029C1862650 @default.
• W1433900029 hasConceptScore W1433900029C204787440 @default.
• W1433900029 hasConceptScore W1433900029C27081682 @default.
• W1433900029 hasConceptScore W1433900029C2776042228 @default.
• W1433900029 hasConceptScore W1433900029C2776719499 @default.
• W1433900029 hasConceptScore W1433900029C2776780178 @default.
• W1433900029 hasConceptScore W1433900029C2778884479 @default.
• W1433900029 hasConceptScore W1433900029C2779028295 @default.
• W1433900029 hasConceptScore W1433900029C2780911369 @default.

• next